Competitive Chemiluminescent Immunoassay for Estradiol Using anN-Functionalized Acridinium Ester

1996 ◽  
Vol 11 (1) ◽  
pp. 23-29 ◽  
Author(s):  
Hiroshi Sato ◽  
Hiroshi Mochizuki ◽  
Yuki Tomita ◽  
Toshio Izako ◽  
Naofumi Sato ◽  
...  
Keyword(s):  
Chemiluminescent Immunoassay ◽  
Acridinium Ester

A Rapid and Sensitive Chemiluminescent Immunoassay of Bisphenol a with NSP-SA-NHS-Labeled

2014 ◽  
Vol 707 ◽  
pp. 7-11
Author(s):  
Fan Fan Yang ◽  
Li Xin Zhu ◽  
Long Xu ◽  
Ren Rong Liu ◽  
Yan Fan ◽  
...  
Keyword(s):  
Bisphenol A ◽  
Inhibitory Concentration ◽  
Limit Of Detection ◽  
Uv Spectrum ◽  
Chemiluminescence Immunoassay ◽  
Highly Sensitive ◽  
Chemiluminescent Immunoassay ◽  
Inhibition Curve ◽  
Sensitive Method ◽  
Acridinium Ester

A novel chemiluminescence immunoassay (CLIA) of Bisphenol A (BPA) with the acridinium ester of NSP-SA-NHS-labeled has been developed. In this study, BVA and NSP-SA-NHS had been coupled with BSA, the UV spectrum results indicated the conjugates which were successfully synthesized. Basing on these luminescence data the inhibition curve of BPA was established, then the linear arrang of the curve was between 0.4 ng/ml and 5 ng/ml, the 50% inhibitory concentration (IC50) was 2.3ng/ml, the lowest limit of detection was 0.1ng/ml, which showed it’s an efficient and highly sensitive method.

One-step chemiluminescent immunoassay of free thyroxin with acridinium-ester-labeled thyroxin evaluated and compared with a two-step radioimmunoassay.

1988 ◽  
Vol 34 (12) ◽  
pp. 2556-2560 ◽  
Author(s):  
J Y Bounaud ◽  
M P Bounaud ◽  
F Begon
Keyword(s):  
Confidence Interval ◽  
Significant Interaction ◽  
Binding Proteins ◽  
Clinical Status ◽  
One Step ◽  
Chemiluminescent Immunoassay ◽  
Therapy Treatment ◽  
Acridinium Ester

Abstract This new one-step chemiluminescent immunoassay of free thyroxin (FT4) involving a thyroxin-immunoglobulin conjugate labeled with acridinium ester (Magic Lite System; Ciba Corning Diagnostics Corp., Medfield, MA) is rapid (one 1-h incubation), requires two calibrators per run, and takes 10 s per sample for the quantification step. Analytical performances were excellent: within- and between-run CVs of less than 10% in the working range, no significant effect of hemolysis, bilirubin, or lipemia, and no significant interaction between the conjugate and the thyroxin-binding proteins. Magic Lite results (y) correlated well with those obtained by the Sclavo (x) two-step radioimmunoassay (Sclavo, Siena, Italy): y = 1.35x + 1.32 (r = 0.94, n = 267, P less than 0.001, Sxy = 6.29). Clinical sensitivities (diagnostic efficiencies) for hypothyroidism and hyperthyroidism were 0.91 and 0.98 for normal interval limits of 12 and 21.5 pmol/L (95% confidence interval). Magic Lite results in situations where patient therapy, treatment, or unusual conditions can result in a lack of correlation between the clinical status and the FT4 values were qualitatively the same as those obtained by the Sclavo assay.

Interleukin-6 chemiluminescent immunoassay on Lumipulse G600 II: analytical evaluation and comparison with three other laboratory analyzers

2020 ◽  
Vol 58 (10) ◽  
pp. e229-e231 ◽  
Author(s):  
Ludovic Glady ◽  
Thomas Lavaux ◽  
Rim Charchour ◽  
Jean-Marc Lacorte ◽  
Jean-Marc Lessinger
Keyword(s):  
Interleukin 6 ◽  
Analytical Evaluation ◽  
Chemiluminescent Immunoassay

scholarly journals Siphon-Controlled Automation on a Lab-on-a-Disc Using Event-Triggered Dissolvable Film Valves

Biosensors ◽  
2021 ◽  
Vol 11 (3) ◽  
pp. 73
Author(s):  
Brian D. Henderson ◽  
David J. Kinahan ◽  
Jeanne Rio ◽  
Rohit Mishra ◽  
Damien King ◽  
...  
Keyword(s):  
Risk Factor ◽  
Limit Of Detection ◽  
C Reactive Protein ◽  
Cvd Risk ◽  
Low Resource Settings ◽  
Low Resource ◽  
Reactive Protein ◽  
Limit Of Quantitation ◽  
Chemiluminescent Immunoassay ◽  
Event Triggered

Within microfluidic technologies, the centrifugal microfluidic “Lab-on-a-Disc” (LoaD) platform offers great potential for use at the PoC and in low-resource settings due to its robustness and the ability to port and miniaturize ‘wet bench’ laboratory protocols. We present the combination of ‘event-triggered dissolvable film valves’ with a centrifugo-pneumatic siphon structure to enable control and timing, through changes in disc spin-speed, of the release and incubations of eight samples/reagents/wash buffers. Based on these microfluidic techniques, we integrated and automated a chemiluminescent immunoassay for detection of the CVD risk factor marker C-reactive protein displaying a limit of detection (LOD) of 44.87 ng mL−1 and limit of quantitation (LoQ) of 135.87 ng mL−1.

scholarly journals Long-Term Longitudinal Evaluation of Six Commercial Immunoassays for the Detection of IgM and IgG Antibodies against SARS CoV-2

Viruses ◽  
2021 ◽  
Vol 13 (7) ◽  
pp. 1244
Author(s):  
Iulia Nedelcu ◽  
Raluca Jipa ◽  
Roxana Vasilescu ◽  
Cristian Băicuș ◽  
Costin-Ioan Popescu ◽  
...  
Keyword(s):  
Clinical Performance ◽  
Sample Selection ◽  
Early Time ◽  
Humoral Response ◽  
High Specificity ◽  
Data Interpretation ◽  
Serum Samples ◽  
Chemiluminescent Immunoassay ◽  
Chemiluminescent Microparticle Immunoassay ◽  
Antibody Levels

The number of serological assays for SARS-CoV-2 has skyrocketed in the past year. Concerns have been raised regarding their performance characteristics, depending on the disease severity and the time of the analysis post-symptom onset (PSO). Thus, independent validations using an unbiased sample selection are required for meaningful serology data interpretation. We aimed to assess the clinical performance of six commercially available assays, the seroconversion, and the dynamics of the humoral response to SARS-CoV-2 infection. The study included 528 serum samples from 156 patients with follow-up visits up to six months PSO and 161 serum samples from healthy people. The IgG/total antibodies positive percentage increased and remained above 95% after six months when chemiluminescent immunoassay (CLIA) IgG antiS1/S2 and electro-chemiluminescent assay (ECLIA) total antiNP were used. At early time points PSO, chemiluminescent microparticle immunoassay (CMIA) IgM antiS achieved the best sensitivity. IgM and IgG appear simultaneously in most circumstances, and when performed in parallel the sensitivity increases. The severe and the moderate clinical forms were significantly associated with higher seropositivity percentage and antibody levels. High specificity was found in all evaluated assays, but the sensitivity was variable depending on the time PSO, severity of disease, detection method and targeted antigen.

Ultrasensitive chemiluminescence immunoassay with enhanced precision for the detection of cTnI amplified by acridinium ester-loaded microspheres and internally calibrated by magnetic fluorescent nanoparticles

Nanoscale ◽  
2021 ◽  
Vol 13 (5) ◽  
pp. 3275-3284
Author(s):  
Huan Zhao ◽  
Qifeng Lin ◽  
Li Huang ◽  
Yunfeng Zhai ◽  
Yuan Liu ◽  
...  
Keyword(s):  
Human Body ◽  
Accurate Diagnosis ◽  
Fluorescent Nanoparticles ◽  
Internal Standards ◽  
Chemiluminescence Immunoassay ◽  
Potential Signal ◽  
Acridinium Ester ◽  
Hydrogel Microspheres

Hydrogel microspheres sensitive to temperature as new potential signal enhancers and magnetic fluorescent nanoparticles as internal standards were used to establish a new CLIA method for the accurate diagnosis of cTnI in the human body.

scholarly journals Prevalence of SARS-CoV-2 infection in Italian pediatric population: a regional seroepidemiological study

2021 ◽  
Vol 47 (1) ◽  
Author(s):  
Manola Comar ◽  
Simone Benvenuto ◽  
Marzia Lazzerini ◽  
Giorgio Fedele ◽  
Egidio Barbi ◽  
...  
Keyword(s):  
Pediatric Population ◽  
Cross Sectional Study ◽  
Nasopharyngeal Swab ◽  
Strongly Correlated ◽  
Igg Antibodies ◽  
Cross Sectional ◽  
Equal Distribution ◽  
Chemiluminescent Immunoassay ◽  
Italian National Institute ◽  
Friuli Venezia Giulia

Abstract Background Data on the effective burden of the SARS-CoV-2 pandemic in pediatric population are very limited, mostly because of the higher rate of asymptomatic or paucisymptomatic cases among children. Updated data on COVID-19 prevalence are needed for their relevance in public health and for infection control policies. In this single-centre cross-sectional study we aimed to assess prevalence of SARS-CoV-2 infection through IgG antibodies detection in an Italian pediatric cohort. Methods The study was conducted in January 2021 among both inpatients and outpatients referring to Research Institute for Maternal and Child Health “Burlo Garofolo” in Trieste, Friuli Venezia-Giulia, Italy, who needed for blood test for any reason. Collected samples were sent to Italian National Institute of Health for analysis through chemiluminescent immunoassay (CLIA). Results One hundred sixty-nine patients were included in the study, with a median age of 10.5 ± 4.1 years, an equal distribution for sex (49.7% female patients), and a 55.6% prevalence of comorbidities. Prevalence of anti-SARS-CoV-2 trimeric Spike protein IgG antibodies was 9.5% (n = 16), with a medium titre of 482.3 ± 387.1 BAU/mL. Having an infected cohabitant strongly correlated with IgG positivity (OR 23.83, 95% CI 7.19–78.98, p < 0.0001), while a cohabitant healthcare worker wasn’t associated with a higher risk (OR 1.53, 95% CI 0.4–5.86, p 0.46). All of the 5 patients who had previously tested positive to a nasopharyngeal swab belonged to the IgG positive group, with a 3-month interval from the infection at most. Conclusion We assessed a 9.5% SARS-CoV-2 seroprevalence in a pediatric cohort from Friuli Venezia-Giulia region in January 2021, showing a substantial increase after the second peak of the pandemic occurred starting from October 2020, compared to 1% prevalence observed by National Institute of Statistics (ISTAT) in July 2020.

Sign in / Sign up

Export Citation Format

Share Document